Analysts Anticipate CONMED Co. (NASDAQ:CNMD) to Announce $0.62 EPS

Equities analysts forecast that CONMED Co. (NASDAQ:CNMDGet Rating) will announce earnings per share of $0.62 for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for CONMED’s earnings. The highest EPS estimate is $0.65 and the lowest is $0.55. CONMED posted earnings per share of $0.63 in the same quarter last year, which suggests a negative year-over-year growth rate of 1.6%. The company is expected to announce its next earnings results after the market closes on Monday, January 1st.

On average, analysts expect that CONMED will report full-year earnings of $3.70 per share for the current financial year, with EPS estimates ranging from $3.67 to $3.73. For the next year, analysts expect that the business will report earnings of $4.27 per share, with EPS estimates ranging from $4.22 to $4.30. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for CONMED.

Separately, StockNews.com started coverage on CONMED in a research note on Thursday, March 31st. They set a “hold” rating on the stock.

NASDAQ:CNMD traded down $1.91 during mid-day trading on Thursday, hitting $152.27. 1,378 shares of the company’s stock traded hands, compared to its average volume of 261,215. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.34 and a quick ratio of 1.16. The firm has a market capitalization of $4.48 billion, a P/E ratio of 78.34, a P/E/G ratio of 3.11 and a beta of 1.53. CONMED has a twelve month low of $117.62 and a twelve month high of $159.11.

CONMED Company Profile (Get Rating)

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.

Featured Articles

Get a free copy of the Zacks research report on CONMED (CNMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.